Search Results for: Can-Fite
Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
– – Israel’s Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, More...
Cipher Pharmaceuticals acquires Canadian rights from Israeli Can-Fite for psoriasis, rheumatoid arthritis treatment
Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Israeli Can-Fite Biopharma (NYSE MKT: CANF) (TASE: More...
Can-Fite Developed Test to Predict Patients’ Response to Drugs
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the development of a commercial predictive More...
Can-Fite Receives Notice of Allowance in US for Psoriasis Patent
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, announced that it has received a Notice of Allowance More...
Can-Fite’s new Drug Fights Diabetes-Related Erectile Dysfunction
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, reported it has received positive data regarding its More...
Israel’s Can-Fite BioPharma Moves Forward with Rheumatoid Arthritis Drug
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the Design of the Rheumatoid Arthritis More...
Can-Fite Treats First Patient with New Cancer Drug
Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, treated the first patient with its CF 102 in a Phase More...
Can-Fite BioPharma Liver Drug Gets US Patent
Israel’s Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, has received a patent in the US for its drug More...
Can-Fite’s CF101 Trial In Dry Eye Syndrome Fails To Meet Endpoints
– Can-Fite CEO Pnina Fishman: The fact that the safety profile of CF101 remains high is encouraging. – CEO Pnina Fishman / Ilan Besor – Can-Fite BioPharma Ltd. ( CANF ) announced today that the More...
Can-Fite Reports Positive Rheumatoid Arthritis Treatment Results
– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board:CANFY) reports positive More...